For millions of adults living with cardiovascular disease, the question of how aggressively to suppress platelet activity — and for how long — remains one of the most consequential decisions in preventive cardiology. A landmark randomized trial published in the New England Journal of Medicine now offers precision-level guidance on this tradeoff, with implications for how high-ischemic-risk patients are managed following acute coronary events or percutaneous coronary intervention.
The trial compared dual antiplatelet therapy (DAPT) — typically aspirin combined with a P2Y12 inhibitor such as clopidogrel — against clopidogrel monotherapy in patients stratified as high ischemic risk. The study enrolled a substantial patient cohort and tracked composite endpoints including myocardial infarction, stroke, and cardiovascular death. Results indicated that extended or intensified DAPT was associated with meaningful reductions in ischemic event rates in the high-risk subgroup, though the bleeding risk profile varied notably across arms — a central tension that has defined this therapeutic debate for over a decade.
This finding arrives in a landscape already shaped by trials like PEGASUS-TIMI 54 and HOST-EXAM, which collectively established that the benefit-risk calculus for prolonged antiplatelet therapy is deeply patient-specific. What distinguishes this contribution is its focus on prospectively defined high-ischemic-risk criteria, moving the field closer to individualized prescribing rather than population-wide duration defaults. That said, this remains a single trial, and replication across different ethnic populations, stent generations, and concomitant anticoagulation regimens will be necessary before practice guidelines shift broadly. Cardiologists will also need to weigh these findings against the growing use of bleeding risk scores like PRECISE-DAPT. For now, this represents a potentially confirmatory and clinically actionable signal for a specific high-risk subset, making it one of the more impactful antiplatelet trials of recent years.